Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Tax Provisions (2023 - 2025)

Protalix BioTherapeutics has reported Tax Provisions over the past 3 years, most recently at $905000.0 for Q4 2025.

  • Quarterly results put Tax Provisions at $905000.0 for Q4 2025, up 54.44% from a year ago — trailing twelve months through Dec 2025 was $1.1 million (up 12.98% YoY), and the annual figure for FY2025 was $996000.0, up 1.01%.
  • Tax Provisions for Q4 2025 was $905000.0 at Protalix BioTherapeutics, up from -$175000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for PLX hit a ceiling of $905000.0 in Q4 2025 and a floor of -$3.5 million in Q4 2023.
  • Median Tax Provisions over the past 3 years was $164000.0 (2023), compared with a mean of -$61500.0.
  • Biggest five-year swings in Tax Provisions: tumbled 170.77% in 2024 and later soared 820.29% in 2025.
  • Protalix BioTherapeutics' Tax Provisions stood at -$3.5 million in 2023, then skyrocketed by 116.87% to $586000.0 in 2024, then skyrocketed by 54.44% to $905000.0 in 2025.
  • The last three reported values for Tax Provisions were $905000.0 (Q4 2025), -$175000.0 (Q3 2025), and $497000.0 (Q2 2025) per Business Quant data.